A clinical trial on patients selected for high mTOR signaling, perhaps using p-S6 as a biomarker, will be required to determine whether mTOR inhibition has potential as an effective therapeutic strategy for some IBD patients. This evidence concerns the gene MTOR and inflammatory bowel disease.